Press Releases July 29, 2026 10:15 AM

SCWorx Receives Nasdaq Hearings Panel Partial Compliance Letter for the Company’s Continued Listing on the Nasdaq Capital Market

SCWorx Receives Partial Nasdaq Compliance Letter, Progressing Towards Regaining Full Listing Standards

By Maya Rios
Share
Twitter Reddit Facebook LinkedIn
SCWX

SCWorx Corp. announced it has received a partial compliance letter from the Nasdaq Hearings Panel confirming that it has met the first requirement to maintain its listing on the Nasdaq Capital Market by achieving the minimum bid price for 20 consecutive trading days. The company continues to execute its compliance plan focused on satisfying all Nasdaq requirements to retain its listing while advancing its healthcare supply chain data platform.

SCWorx Receives Nasdaq Hearings Panel Partial Compliance Letter for the Company’s Continued Listing on the Nasdaq Capital Market
SCWX
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • SCWorx met the initial Nasdaq minimum bid price requirement of at least $1.00 per share for 20 consecutive trading days.
  • The company remains subject to ongoing compliance conditions and must notify Nasdaq of any material changes affecting its listing eligibility.
  • SCWorx is focused on expanding its healthcare supply chain data management solutions platform and creating long-term shareholder value.

MIDDLETON, MA, July 29, 2026 (GLOBE NEWSWIRE) -- SCWorx Corp. ("SCWorx" or the "Company"), a provider of data normalization and supply chain solutions for the healthcare industry, today announced that it has received a partial compliance letter from the Nasdaq Hearings Panel (the "Panel") confirming completion of the first benchmark for the Company’s approved plan to regain compliance for continued listing on The Nasdaq Capital Market.

Under the terms of the Panel's previous decision, SCWorx must demonstrate compliance with Nasdaq's minimum bid price requirement by achieving a closing bid price of at least $1.00 per share for a minimum of twenty (20) consecutive trading days, as required under Nasdaq Listing Rule 5815(c)(4).

The company must still immediately notify Nasdaq of any material changes to its compliance plan or any event, condition, or circumstance that could affect the Company's ability to satisfy the requirements of the exception granted previously. The Panel also reserved the right to reconsider the terms of the exception should any developments arise that, in the Panel's judgment, make continued listing of the Company's securities inadvisable or unwarranted.

"We appreciate the Panel's continued consideration and for the opportunity to continue our Nasdaq listing while we execute the next phases of our compliance plan," said Tim Hannibal, President and Chief Executive Officer of SCWorx. "Maintaining our Nasdaq listing remains a strategic priority as we continue to focus on expanding customer relationships, advancing our healthcare supply chain data management platform, and creating long-term value for shareholders."

The Company intends to take all actions necessary to satisfy the conditions established by the Panel and will continue to keep investors informed regarding its progress.

About SCWorx Corp.

SCWorx is a provider of data management and analytics solutions focused on improving operational efficiency, data accuracy, and cost savings for healthcare organizations. The Company’s platform enables the normalization, aggregation, and analysis of complex data sets to support supply chain optimization, financial performance, and regulatory compliance.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are based on current expectations and assumptions and involve risks and uncertainties that could cause actual results to differ materially. SCWorx undertakes no obligation to update any forward-looking statements except as required by law.

Investor Relations Contact:

SCWorx Investor Relations

[email protected]


Risks

  • Failure to fully meet all Nasdaq compliance criteria could result in delisting, impacting stock liquidity and investor confidence.
  • Market or operational challenges in expanding customer relationships and platform adoption in the healthcare sector may affect financial performance.
  • Uncertainties inherent in forward-looking statements, including regulatory and market risks in the healthcare technology sector, may impact future results.

More from Press Releases

Hyperion DeFi Schedules First Quarter Earnings Call for Wednesday, August 12 at 5:00 p.m. ET Jul 29, 2026 The Lancet Publishes HOPE-3 Data for Capricor Therapeutics’ Deramiocel in Duchenne Muscular Dystrophy Jul 29, 2026 Smith+Nephew’s TESSA™ Spatial Surgery System granted De Novo classification by the FDA sparking a generational leap in Sports Medicine for personalized planning and procedural innovation Jul 29, 2026 Performance Shipping Inc. Reports Financial Results For The Second Quarter and Six Months Ended June 30, 2026 Jul 29, 2026 Alvotech announces successful closure of FDA inspection of manufacturing facility Jul 29, 2026